Table 3.
Univariate Cox regression analysis for HBVr (N = 26).
| HBVr (N = 2) | No HBVr (N = 24) | HR (95% CI) | P-value | |
|---|---|---|---|---|
| Female | 0 (0) | 7 (29.2) | 0.016 (0.000-1451.874) | 0.480 |
| Age > 60 years | 0 (0) | 12 (50) | 0.033 (0.000-62403.444) | 0.644 |
| Previous therapies≥4 | 2 (11.8) | 15 (88.2) | 0.849 (0.291-2.480) | 0.765 |
| Zanubrutinib | 1 (50) | 7 (29.2) | 4.243 (0.231-78.065) | 0.331 |
| HBsAb-Positive | 1 (50) | 12 (50) | 1.254 (0.077-20.400) | 0.874 |
| HBeAb-Positive | 1 (50) | 12 (50) | 1 (0.063-15.988) | 1 |
Comparisons in 26 patients with resolved HBV infection.
Data are presented as n (%) of patients.
HBVr, hepatitis B virus reactivation; HR, Hazard Ratio; CI, confidence interval; HbsAb, hepatitis B surface antibody; HbeAb, hepatitis B e antibody.